使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings, and welcome to Align Technology Third Quarter 2017 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
各位好,歡迎參加 Align Technology 2017 年第三季財報電話會議。(接線員指示) 提醒各位,本次會議將被錄音。
I'd now like to turn the conference over to your host, Shirley Stacy, Vice President of Corporate and Investor Communications. Please go ahead.
現在我想把會議交給今天的主持人:企業與投資人溝通副總裁 Shirley Stacy。請開始。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Good afternoon, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO. We issued third quarter 2017 financial results today via Marketwired, which is available on our website at investor.aligntech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5:30 p.m. Eastern time through 5:30 p.m. Eastern time on November 9. To access the telephone replay, domestic callers should dial (877) 660-6853 with conference number 13671493 followed by #. International callers should dial (201) 612-7415, with the same conference number.
各位下午好,感謝各位加入我們。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同出席電話會議的有總裁暨執行長 Joe Hogan,以及財務長 John Morici。我們已於今日透過 Marketwired 發布 2017 年第三季財務結果,並可於我們網站 investor.aligntech.com 取得。今天的電話會議將以音訊網路直播,並將在我們網站上存檔約 12 個月。電話重播預計將於今日約下午 5:30美東時間提供,並持續至 11 月 9 日下午 5:30美東時間。欲收聽電話重播,美國境內來電者請撥打 (877) 660-6853,輸入會議編號 13671493 後按 #。國際來電者請撥打 (201) 612-7415,會議編號相同。
As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlook and the expected financial results for the fourth quarter of 2017. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission.
提醒各位,今天簡報人員所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望以及 2017 年第四季預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容已在我們最近向美國證券交易委員會提交的定期報告中更詳細說明。
Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements. We have posted historical financial statements, including the corresponding reconciliations and our third quarter conference call slides on our website, under Quarterly Results. Please refer to these files for more detailed information. With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
實際結果可能會有重大差異,Align 明確表示不承擔更新任何前瞻性陳述之義務。我們已在網站「季度結果」專區張貼歷史財務報表(含相應調節表)以及第三季電話會議簡報投影片。請參閱這些檔案以取得更詳細資訊。接下來,我將把電話會議交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, Shirley. Good afternoon, and thanks for joining us. On our call today, I'll provide some highlights from the quarter and then briefly discuss the performance of our 2 operating segments, clear aligners and intra-oral scanners. John will provide more detail on our financial results and discuss our outlook for the fourth quarter. Following that, I'll come back and summarize a few key points and open the call up to questions.
謝謝你,Shirley。各位下午好,感謝各位加入我們。在今天的電話會議中,我將先分享本季的一些重點,接著簡要說明我們兩個營運部門——透明牙套與口內掃描器——的表現。John 將更詳細說明我們的財務結果,並討論第四季展望。之後我會回來總結幾個關鍵重點,並開放提問。
I'm pleased to report another strong quarter in Q3, results have exceeded our expectations across our key financial metrics, including revenue, volume, margins and EPS. Our Q3 revenues increased 38.3% year-over-year, driven by increased Invisalign volumes across all of our geographies as well as strong growth from iTero scanners. Our strong Q3 results also reflect accelerated growth from teenagers in both North America and Asia Pacific, with total Invisalign shipments to teens up 46.3% year-over-year, and up 26.5% from Q2.
我很高興報告第三季再度交出強勁的一季,我們的結果在多項關鍵財務指標上都超出預期,包括營收、出貨量、毛利率與每股盈餘(EPS)。第三季營收年增 38.3%,主要受惠於各地區 Invisalign 出貨量增加,以及 iTero 掃描器的強勁成長。第三季的強勁表現也反映出北美與亞太地區青少年市場的加速成長;第三季青少年 Invisalign 出貨量年增 46.3%,較第二季成長 26.5%。
On a sequential basis, revenues increased 8.1%, driven by continued strength across Asia Pacific, which offset expected seasonality in Europe as well as higher-than-expected revenues from shipments to SmileDirectClub.
以季比來看,營收成長 8.1%,主要由亞太地區持續強勁的表現所帶動,抵銷了歐洲預期的季節性因素,以及對 SmileDirectClub 出貨帶來的高於預期營收。
For North America, Q3 Invisalign case volume was down 1.1% sequentially, reflecting a decrease in GP dentist channel due to less patient traffic and fewer days in the office from the summer holidays. In addition, as a result of the devastation caused by Hurricane Harvey and Irma, we estimate that our North American volumes were lower by approximately 1,500 cases in Q3, mostly adults. These declines were partially offset by strong growth from the Ortho channel, especially teens. On a year-over-year basis, North America was up 25%, reflecting strong growth from the Ortho channel, driven by an increase in teen patients and Invisalign Express/Lite products.
就北美而言,第三季 Invisalign 病例量較前一季下滑 1.1%,反映出一般牙醫(GP)通路因暑期假期導致病患來診量較少、診所開診天數減少。此外,由於哈維颶風與艾瑪颶風造成的破壞,我們估計第三季北美出貨量約少了 1,500 例,且多為成人病例。上述下滑部分被矯正專科(Ortho)通路的強勁成長所抵銷,尤其是青少年。以年比來看,北美成長 25%,反映矯正專科通路的強勁成長,主要由青少年病患增加以及 Invisalign Express/Lite 產品所帶動。
Q3 Invisalign volume for international doctors is up 6.8% sequentially, driven primarily by Asia Pacific region, which offset expected summer seasonality declines in EMEA. On a year-over-year basis, Invisalign volume is up 47.4%, reflecting strong growth from both APAC and EMEA. In EMEA, Q3 volumes were up 37.6% year-over-year led by our core European markets, particularly Spain, U.K. and France. We also saw strong growth across all of our smaller expansion markets, which includes Central and Eastern Europe, Benelux, Middle East and Africa, the Nordics and Russia.
第三季國際醫師的 Invisalign 病例量較前一季成長 6.8%,主要由亞太地區帶動,抵銷了 EMEA 地區預期的夏季季節性下滑。以年比來看,Invisalign 病例量成長 47.4%,反映 APAC 與 EMEA 皆有強勁成長。在 EMEA,第三季病例量年增 37.6%,由我們的核心歐洲市場帶動,尤其是西班牙、英國與法國。我們也看到所有較小的擴張市場均有強勁成長,包括中東歐、比荷盧、中東與非洲、北歐以及俄羅斯。
In APAC, Q3 volumes were up 57.4% year-over-year with record Invisalign volume across all country markets, led primarily by China. Q3 marked the first quarter in which China was our second largest market in the world, behind the United States. Our active customer base in APAC is almost tripled year-over-year, with over 1,500 docs trained in Q3, mostly within China.
在 APAC,第三季病例量年增 57.4%,所有國家市場的 Invisalign 病例量皆創新高,主要由中國帶動。第三季是中國首次成為我們全球第二大市場,僅次於美國。我們在 APAC 的活躍客戶基礎年增近三倍;第三季受訓醫師超過 1,500 位,且多數在中國。
Turning to the teen market. Over 69,800 teenagers started treatment with Invisalign clear aligners in Q3, up 26.5% sequentially and 46.3% year-over-year, reflecting a very strong summer teen season and accelerating growth rates. North American ortho teen cases increased 22.9% sequentially and 43.6% year-over-year, reflecting our continued efforts to drive adoption of teenage patients through sales initiatives and our direct-to-consumer campaign emphasizing teens and moms.
接著談青少年市場。第三季有超過 69,800 名青少年開始使用 Invisalign 透明牙套治療,較前一季成長 26.5%,較去年同期成長 46.3%,反映非常強勁的暑期青少年旺季以及加速的成長率。北美矯正專科青少年病例較前一季成長 22.9%,較去年同期成長 43.6%,反映我們持續透過銷售推動方案以及以青少年與媽媽為主軸的直面消費者(DTC)行銷活動,來提升青少年病患的採用。
For international, Q3 teen cases increased 36.7% sequentially and 65.7% year-over-year, driven by accelerated growth across the APAC region, primarily led by China. The introduction of the Invisalign treatment with mandibular advancement is helping to raise visibility for Invisalign treatment of teenagers and contributed to some of the growth in the APAC region.
在國際市場,第三季青少年病例較前一季成長 36.7%,較去年同期成長 65.7%,主要由 APAC 地區的加速成長所帶動,且以中國為主。推出具下顎前移(mandibular advancement)功能的 Invisalign 治療,有助於提升 Invisalign 青少年治療的能見度,並對 APAC 地區的部分成長有所貢獻。
Recall that Invisalign treatment of mandibular advancement is the first clear aligner solution for Class II correction that advances the mandible while moving teeth at the same time. Mandibular advancement is integral to increasing teen adoption. Approximately 30% to 45% of teen cases globally need Class II correction. Based on early indications, we are seeing a positive correlation between those customers who use our mandibular advancement feature and increased teen utilization. One example is Dr. Lekic in Canada, who is seeing the benefits of switching from an analog to digital method of orthodontics, not just with mandibular advancement but with Invisalign treatment in general. With the launch of mandibular advancement and because of the renewed commitment to being fully digital and phasing out the use of metal braces, Dr. Lekic has started 162 patients in Invisalign treatment since Q2 '17. Of those 120 were teenagers and 24 were treated with mandibular advancement feature. This is compared to only 3 Invisalign cases in 2016 and only 1 Invisalign case in the first quarter of this year. That's an amazing transformation for Dr. Lekic's business and speaks to the impact of digital approach for younger patients. Invisalign treatment with mandibular advancement is not available in United States yet as it's currently pending FDA approval.
請記得,具下顎前移的 Invisalign 治療是第一個用於第二類咬合(Class II)矯正的透明牙套解決方案,可在移動牙齒的同時推進下顎。下顎前移對於提升青少年採用率至關重要。全球約有 30% 至 45% 的青少年病例需要第二類咬合矯正。根據初步跡象,我們看到使用下顎前移功能的客戶與青少年使用率提升之間呈現正向關聯。其中一個例子是加拿大的 Lekic 醫師,他看到了從傳統類比矯正方式轉向數位方式的好處,不僅是在下顎前移方面,也包括 Invisalign 治療整體。隨著下顎前移的推出,以及重新承諾全面數位化並逐步淘汰金屬牙套的使用,Lekic 醫師自 2017 年第二季以來已讓 162 位病患開始 Invisalign 治療。其中 120 位為青少年,24 位使用了下顎前移功能治療。相較之下,他在 2016 年僅有 3 例 Invisalign 病例,而今年第一季也只有 1 例 Invisalign 病例。這對 Lekic 醫師的業務而言是驚人的轉變,也說明數位化方式對年輕病患的影響。具下顎前移功能的 Invisalign 治療目前尚未在美國上市,因仍在等待 FDA 核准。
Our consumer marketing programs continue to increase demand for Invisalign treatment and are key to adoption in both the teen and adult segments. Each year, we invest millions in consumer advertising and social media campaigns that raise awareness, create preference and help consumers find an Invisalign practice near them. In 2017, we increased our investment in consumer marketing by 60%, which we believe is contributing to our strong growth. But despite our efforts, most of the consumers interested in Invisalign treatment still end up in metal braces or don't start any type of orthodontic treatment at all. This as a phenomenon isn't new and we've been working for years to identify gaps like these and develop solutions that turn more consumers into Invisalign patients for our customers.
我們的消費者行銷計畫持續提升對 Invisalign 治療的需求,並且是青少年與成人兩大族群採用的關鍵。每年,我們投入數百萬美元於消費者廣告與社群媒體活動,以提高認知、建立偏好,並協助消費者在住家附近找到提供 Invisalign 的診所。2017 年,我們將消費者行銷投資提高了 60%,我們相信這正在促成我們強勁的成長。但儘管我們付出努力,多數對 Invisalign 治療有興趣的消費者最後仍選擇金屬牙套,或根本沒有開始任何類型的矯正治療。這種現象並不新,我們多年來一直致力於找出這類落差並開發解決方案,讓更多消費者能為我們的客戶轉化為 Invisalign 病患。
In January, we launched a new consumer capture program with the Smile Concierge Team in Raleigh, North Carolina whose goal is to reach more consumers one-on-one and ensure that anyone that contacts us directly has the best experience with Invisalign brand, beginning to end. Our Smile Concierge service educates consumers on the benefits of Invisalign treatment, answers their questions and helps them to schedule an appointment in Invisalign providers from our next level partnership listed as VIP on invisalign.com.locator. The team also follows up with consumers through digital apps and e-mail to find out whether they keep their appointment and start Invisalign treatment. It's really exciting to see how something is as simple as direct personal touch has resulted in such positive response from our consumers and our doctors. The team receives incredible feedback from consumers every day who appreciate the white-glove service we provide, which is translating into shorter research cycles for the average consumer interested in that Invisalign treatment and a win-win for Align, our customers and consumers.
今年 1 月,我們在北卡羅來納州羅利市推出了由 Smile Concierge Team(微笑禮賓團隊)執行的全新消費者導流計畫,目標是一對一接觸更多消費者,並確保任何直接聯繫我們的人,從頭到尾都能獲得最佳的 Invisalign 品牌體驗。我們的 Smile Concierge 服務向消費者說明 Invisalign 治療的優點、回答問題,並協助他們在 invisalign.com.locator 上列為 VIP 的下一級合作夥伴名單中,預約 Invisalign 供應商的門診。團隊也會透過數位應用程式與電子郵件追蹤消費者,了解他們是否如期赴約並開始 Invisalign 治療。看到如此簡單的直接個人互動就能帶來消費者與醫師如此正向的回饋,真的令人振奮。團隊每天都收到消費者極佳的回饋,他們很感謝我們提供的白手套式服務;這也讓一般對 Invisalign 治療有興趣的消費者縮短了研究與比較的週期,並為 Align、我們的客戶與消費者帶來三贏。
Over the past 10 months, our Smile Concierge Team has contacted 50,000 consumers who took a smile assessment on invisalign.com and scheduled 20,000 consultations with nearly 800 Invisalign practices across the U.S. To date, 5,000 have already started treatment with an Invisalign provider, which equates to millions of dollars in revenue to Invisalign practices. And we're just getting started. Our new Smile Concierge service is not only helping turn more consumers into Invisalign patients, we're also learning a lot about consumer conversion. For example, convenience and speed of contact are critical to conversion. If we can't schedule an appointment for a consumer to see a doctor within 72 hours, meaning they can't get onto the doctor's schedule within 3 days, the likelihood of that consumer converting to an Invisalign patient drops by 40%.
過去 10 個月,我們的 Smile Concierge Team 已聯繫 50,000 名在 invisalign.com 完成微笑評估的消費者,並在全美近 800 家 Invisalign 診所安排了 20,000 次諮詢。迄今已有 5,000 人開始在 Invisalign 供應商處接受治療,這相當於為 Invisalign 診所帶來數百萬美元的營收。而這才剛開始。我們新的 Smile Concierge 服務不僅協助將更多消費者轉化為 Invisalign 病患,也讓我們對消費者轉化有了更多洞察。例如,便利性與聯繫速度對轉化至關重要。如果我們無法在 72 小時內替消費者安排看診,也就是無法在 3 天內排進醫師的行程,該消費者轉化為 Invisalign 病患的可能性會下降 40%。
On top of that, for the consumers that get scheduled for a consultation, 65% of them cite financial concerns as the reason they don't start treatment, with 25% of them stating that a high down payment in the practice is the main barrier to acceptance. With that in mind, as part of our smile concierge service, we've just launched a patient financing pilot that addresses consumer financing concerns as well as insurance coverage for orthodontic treatment. In developing this pilot, it's important for us to find a solution that offers consumers the ability to customize their own down payment, monthly payment and interest rate in a way that they can fit into any budget. Equally important is providing an end-to-end digital workflow for both the consumer and the doctor, and with our new third-party finance as a partner, we've done just that. When consumers finance their treatment through us, Invisalign providers no longer pay Align. Instead they just receive payment for the treatment fee minus Align's lab fee. By changing the financial relationship between the patient, Align and the provider, Invisalign treatment becomes a revenue source for the provider and eliminates the need for them to pass on the high down payments to patients.
此外,對於已安排諮詢的消費者,有 65% 表示財務疑慮是他們未開始治療的原因,其中 25% 指出診所要求的高額頭期款是接受治療的主要障礙。基於此,作為 smile concierge 服務的一部分,我們剛推出病患融資試點計畫,以解決消費者的融資疑慮以及矯正治療的保險給付問題。在開發此試點時,對我們而言重要的是找到一個解決方案,讓消費者能以符合任何預算的方式,自行客製頭期款、每月付款金額與利率。同樣重要的是,為消費者與醫師提供端到端的數位化工作流程;透過我們新的第三方金融合作夥伴,我們已做到這一點。當消費者透過我們為其治療進行融資時,Invisalign 供應商將不再向 Align 付款。相反地,他們只會收到治療費用款項,扣除 Align 的製作(lab)費用後的淨額。透過改變病患、Align 與供應商之間的財務關係,Invisalign 治療成為供應商的營收來源,並消除供應商將高額頭期款轉嫁給病患的必要。
Finally, we've also learned what's important for consumers when it comes to choosing an Invisalign practice and digital technology really matters. As part of the smile concierge referral process, consumers are offered the top 3 Invisalign practices in their areas and it turns out that the iTero scanner is one of the key influencers. While this isn't surprising to us, it is important to be able to validate another example of digital technology like our iTero intra-oral scanner, replacing an old analogue process like PVC impressions (sic) [PVS impressions].
最後,我們也了解到消費者在選擇 Invisalign 診所時重視的因素,而數位科技確實非常重要。在 smile concierge 的轉介流程中,消費者會獲得其所在地區排名前 3 的 Invisalign 診所推薦,而結果顯示 iTero 掃描儀是關鍵影響因素之一。雖然這對我們而言並不意外,但能夠再次驗證數位科技(例如我們的 iTero 口內掃描儀)正在取代像 PVS 印模(原文誤寫為 PVC impressions(sic)[PVS impressions])這類舊式類比流程,仍然很重要。
With that, let's review the results for the iTero business. Q3 was a strong quarter for iTero and better-than-expected with revenues up 25% year-over-year on record iTero scanner shipments. The iTero scanner is central to restorative workflows and key to our GP strategy. In Q3, we saw a nice uptake by GP dentists with record contracts at our GP Summit in September. Q3 results also reflect the initial uptake of iTero scanner from its first commercial availability in Japan as well as from our new distribution agreement with Patterson Dental in the United States and Canada. Use of the iTero scanners for Invisalign case submission in place of PVS impressions continues to expand and remains a positive catalyst for Invisalign utilization. For Q3, total Invisalign cases submitted with a digital scanner in North America increased to a record 61.9%, up from 48.8% in Q3 of last year.
接下來,我們來回顧 iTero 業務的成果。第三季對 iTero 而言表現強勁,且優於預期;在 iTero 掃描儀出貨量創新高的帶動下,營收年增 25%。iTero 掃描儀是修復(restorative)工作流程的核心,也是我們全科牙醫(GP)策略的關鍵。第三季,我們看到全科牙醫的採用明顯提升,並在 9 月的 GP 高峰會上創下合約數新高。第三季的結果也反映 iTero 掃描儀在日本首次商業化上市後的初期採用情況,以及我們在美國與加拿大與 Patterson Dental 的新經銷協議所帶來的貢獻。以 iTero 掃描儀提交 Invisalign 病例、取代 PVS 印模的使用持續擴大,並仍是推動 Invisalign 使用量的正向催化因素。第三季,北美使用數位掃描儀提交的 Invisalign 病例占比提升至創紀錄的 61.9%,高於去年第三季的 48.8%。
Overall, we continue to be excited about the long-term potential for At Home, Doctor-Directed market and are pleased with our equity investment and supply agreement with SmileDirectClub. For Q3, aligner shipments to SmileDirectClub, or SDC, were higher-than-expected and more than doubled sequentially, reflecting continued strong volume growth as well as a shift to Align manufacturing more of SDCs aligners than what SDC internally produces. As SDC's exclusive third-party supplier, this quarter we produced about 2/3 of their clear aligner volume as compared to only 1/3 in the prior 2 quarters. While this shift was not anticipated, our world-class manufacturing operations can accommodate changes in SDC's order flow easily. We're pleased to be able to support their continued rapid growth.
整體而言,我們仍對「居家、由醫師主導」(At Home, Doctor-Directed)市場的長期潛力感到振奮,並對我們對 SmileDirectClub 的股權投資與供貨協議感到滿意。第三季,出貨給 SmileDirectClub(SDC)的牙套出貨量高於預期,且較前一季增加逾一倍,反映其持續強勁的量能成長,以及 Align 製造的 SDC 牙套占比提高、相較於 SDC 自行內製的比例上升。作為 SDC 的獨家第三方供應商,本季我們生產了其透明牙套總量約 2/3,而前兩季僅約 1/3。雖然這一轉變並非原先預期,但我們世界級的製造營運能輕鬆因應 SDC 訂單流的變化。我們很高興能支持他們持續快速的成長。
With that, I'll now turn it over to John.
接下來,我把時間交給 John。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Thanks, Joe. Now for our Q3 financial results. Total company revenue for the third quarter was a record $385.3 million, up 8.1% from the prior quarter and up 38.3% from the corresponding quarter, a year ago. Clear aligner revenue up $341.6 million, was up 6.4% sequentially on higher-than-expected volume and favorable foreign exchange rates as well as increased revenue from shipments to SDC. Year-over-year clear aligner revenue growth of 40.2% reflected strong Invisalign shipment growth across all customer channels and geographies, increased Invisalign prices and revenue from shipments to SDC. Q3 Invisalign ASPs were up sequentially, approximately $25 from Q2 to $1,310, reflecting favorable foreign exchange, a favorable shift in our product mix and price increases, partially offset by increased promotional discounts. On a year-over-year basis, Q3 Invisalign ASPs were also up $25, reflecting price increases, an increase in additional aligner revenue, favorable foreign exchange, partially offset by increased promotional discounts.
謝謝,Joe。接著說明我們第三季的財務結果。第三季公司總營收創紀錄,達 3.853 億美元,較前一季成長 8.1%,較去年同期成長 38.3%。透明牙套營收為 3.416 億美元,受惠於高於預期的出貨量、有利的匯率,以及對 SDC 出貨帶來的營收增加,較前一季成長 6.4%。透明牙套營收年增 40.2%,反映 Invisalign 在所有客戶通路與各地區的出貨強勁成長、Invisalign 價格上調,以及對 SDC 出貨帶來的營收。第三季 Invisalign 平均銷售單價(ASP)較前一季上升,約較第二季增加 25 美元至 1,310 美元,反映有利匯率、產品組合的有利變化與價格上調,但部分被促銷折扣增加所抵銷。以年對年來看,第三季 Invisalign ASP 亦增加 25 美元,反映價格上調、額外牙套營收增加與有利匯率,但部分被促銷折扣增加所抵銷。
For the third quarter, total Invisalign shipments of 236,100 cases were up 1.8% sequentially, driven primarily by our Asia Pacific doctors and North American orthodontists. Year-over-year, Invisalign case volume growth was up 32.8%, driven by growth across all regions as well as expansion of our customer base predominantly from Asia Pacific. For North American orthodontists, Q3 Invisalign case volume was up 1.8% sequentially and up 31.9% year-over-year. For North American GP dentists, Invisalign case volume was down 5.2% sequentially and up 15.9% year-over-year. For international doctors, Invisalign case volume was up 6.8% sequentially, and up 47.4% year-over-year.
第三季 Invisalign 總出貨量為 236,100 件(病例),較前一季成長 1.8%,主要由亞太地區醫師與北美矯正專科醫師所帶動。與去年同期相比,Invisalign 病例量成長 32.8%,動能來自各區域的成長,以及客戶基礎的擴張(主要來自亞太地區)。就北美矯正專科醫師而言,第三季 Invisalign 病例量較前一季成長 1.8%,較去年同期成長 31.9%。就北美一般牙醫(GP)而言,Invisalign 病例量較前一季下滑 5.2%,較去年同期成長 15.9%。就國際地區醫師而言,Invisalign 病例量較前一季成長 6.8%,較去年同期成長 47.4%。
Our scanner and services revenue for the third quarter was $43.7 million, up 23.2% sequentially and up 25% year-over-year, primarily due to our continued investment in go-to-market activities in APAC and EMEA as well as the initial uptake of the iTero scanner from its first commercial availability in Japan.
第三季掃描儀與服務營收為 4,370 萬美元,較前一季成長 23.2%,較去年同期成長 25%,主要因我們持續在亞太(APAC)與歐洲、中東及非洲(EMEA)投入市場推廣(go-to-market)活動,以及 iTero 掃描儀在日本首次商業化上市後的初期採用帶動。
Moving on to gross margin. Third quarter overall gross margin was 75.9%, down 0.1 point sequentially and up 0.8 points year-over-year. Clear aligner gross margin for the third quarter was 77.9%, down 0.2 points sequentially, primarily due to an increase in aligners per case driven by additional aligners, partially offset by higher clear aligner ASPs. Clear aligner gross margin was up 0.2 points year-over-year, primarily due to leveraging our manufacturing costs over higher volumes. Scanner gross margin for the third quarter was 60%, up 3.3 points sequentially, primarily due to higher ASPs. Scanner segment gross margin was up 2.9 points year-over-year, primarily a result of lower service costs.
接著談毛利率。第三季整體毛利率為 75.9%,較前一季下降 0.1 個百分點,較去年同期上升 0.8 個百分點。第三季透明牙套(clear aligner)毛利率為 77.9%,較前一季下降 0.2 個百分點,主要因每病例牙套數增加(由額外牙套帶動),部分被較高的透明牙套平均售價(ASP)所抵銷。透明牙套毛利率較去年同期上升 0.2 個百分點,主要因在較高出貨量下攤提製造成本、提升成本效率。第三季掃描儀毛利率為 60%,較前一季上升 3.3 個百分點,主要因平均售價(ASP)提高。掃描儀事業部毛利率較去年同期上升 2.9 個百分點,主要因服務成本降低。
Q3 operating expenses were $193.7 million, up sequentially by $6.4 million or 3.4%, primarily related to increased global headcount. On a year-over-year basis, Q3 operating expenses were up 31.7%, reflecting increased headcount and continued investment in our go-to-market activities critical to the growth of our business.
第三季營業費用為 1.937 億美元,較前一季增加 640 萬美元(或 3.4%),主要與全球人力編制增加有關。與去年同期相比,第三季營業費用增加 31.7%,反映人力增加以及持續投入對業務成長至關重要的市場推廣(go-to-market)活動。
Our third quarter operating margin was 25.6%, up 2.2 points sequentially and up 3.3 points year-over-year. This sequential increase in operating margin relates primarily to increased clear aligner volume. On a year-over-year basis, the increase in operating margin primarily reflects higher revenue and lower cost per case, partially offset by increased headcount and higher marketing expenses.
第三季營業利益率為 25.6%,較前一季上升 2.2 個百分點,較去年同期上升 3.3 個百分點。營業利益率的季增主要與透明牙套出貨量增加有關。與去年同期相比,營業利益率提升主要反映營收增加與每病例成本下降,部分被人力增加與行銷費用提高所抵銷。
With regards to our third quarter tax provision, our tax rate was 17.9%, which includes $1.7 million in excess tax benefits and is down by approximately 0.5 points compared to 18.4% in the same quarter last year, primarily due to the 2017 adoption of ASU 2016-09, which requires excess tax benefits related to stock-based compensation be recognized as a reduction to tax expense. Hence certain onetime tax charges incurred in the prior year from implementing our new international corporate tax structure. The revenue and costs to supply aligners to SmileDirectClub are included in our operating profit and reported results. Additionally, we also report our share of SmileDirectClub's losses below operating margin and our tax provision and is entitled, Equity in Losses of Investee, net of tax. Our share of SDC's loss, net of tax, in Q3, was approximately $1.6 million, decreasing our diluted earnings per share by $0.02. Third quarter diluted earnings per share was $1.01, up 18.8% sequentially and up 60.3% compared to prior year.
就第三季所得稅費用而言,我們的有效稅率為 17.9%,其中包含 170 萬美元的超額稅務利益(excess tax benefits),較去年同季 18.4% 約下降 0.5 個百分點,主要因 2017 年採用 ASU 2016-09;該準則要求將與股份基礎給付相關的超額稅務利益認列為所得稅費用的減項。因此,前一年因導入新的國際公司稅務架構而產生的部分一次性稅務費用。供應 SmileDirectClub 牙套的相關營收與成本已納入我們的營業利益與揭露之財務結果。此外,我們亦將 SmileDirectClub 虧損中屬於我們的份額列於營業利益率與所得稅費用之下,科目為「被投資公司虧損之權益法認列(Equity in Losses of Investee),扣除稅後」。第三季我們分攤 SDC 的稅後虧損約為 160 萬美元,使稀釋每股盈餘減少 0.02 美元。第三季稀釋每股盈餘為 1.01 美元,較前一季成長 18.8%,較去年同期成長 60.3%。
Moving on to the balance sheet. As of the third quarter, cash, cash equivalents and marketable securities, including both short- and long-term investments, were $739.9 million (sic) [$737.9 million]. This compared to $676.6 million at the end of Q2, an increase of approximately $61.3 million, primarily related to earnings growth. Of our $737.9 million of cash, cash equivalents and marketable securities, $236.3 million was held by the U.S. and $501.6 million was held by our international entities. Q3 accounts receivable balance was $321.3 million, up approximately 10.2% sequentially. Our overall DSO was 75 days, up 1 day sequentially and down 3 days from 78 days in Q3 last year. We anticipate that our DSOs will decline over the next few quarters.
接著看資產負債表。截至第三季末,現金、約當現金與有價證券(包含短期與長期投資)為 7.399 億美元(原文如此)[7.379 億美元]。相較第二季末的 6.766 億美元,約增加 6,130 萬美元,主要與獲利成長有關。在 7.379 億美元的現金、約當現金與有價證券中,2.363 億美元由美國持有,5.016 億美元由海外實體持有。第三季應收帳款餘額為 3.213 億美元,較前一季約增加 10.2%。整體應收帳款週轉天數(DSO)為 75 天,較前一季增加 1 天,較去年第三季的 78 天減少 3 天。我們預期未來幾季 DSO 將下降。
Cash flow from operations for the third quarter was $118.1 million, up $58.3 million compared to the prior year. Free cash flow for the quarter defined as cash flow from operations less capital expenditures, amounted to $70 million. Capital expenditures for the third quarter were $48.1 million, primarily relating to building purchases and improvements, equipment purchases for additional manufacturing capacity as well as our global expansion efforts.
第三季營運活動現金流量為 1.181 億美元,較去年同期增加 5,830 萬美元。本季自由現金流量(定義為營運活動現金流量減資本支出)為 7,000 萬美元。第三季資本支出為 4,810 萬美元,主要與購置與改善建物、為增加製造產能而購置設備,以及我們的全球擴張計畫相關。
During the third quarter, we concluded our previously announced $50 million accelerated stock repurchase. We received a total of 0.4 million shares under the ASR at a weighted average share price of $146.48. We have $250 million remaining for repurchases under the existing stock repurchase authorization.
第三季期間,我們完成先前公告的 5,000 萬美元加速庫藏股買回(ASR)。在該 ASR 下,我們共收到 40 萬股,按加權平均股價 146.48 美元計。依現行股票回購授權,我們尚餘 2.5 億美元可用於回購。
With that, let's turn to our Q4 outlook and the factors that inform our view, starting with the demand outlook. For international, we expect Invisalign volume to be up from Q3 as EMEA customers return from seasonally slower summer holidays, partially offset by slight decrease in APAC as the greater China market observes the Golden Week holiday. For North America, we expect Invisalign volume to be up sequentially, reflecting a seasonally stronger quarter, partially offset by some lingering effects of Hurricanes Harvey and Irma. For our scanner business, we expect a slight sequential increase reflecting a typical strong end of the year demand for capital equipment. Q4 sequential growth reflects the benefit from orders taken at our North America GP Summit in Q3 and global expansion.
接下來我們談第四季展望,以及支撐我們觀點的因素,先從需求展望開始。就國際市場而言,我們預期 Invisalign 量將較第三季增加,因 EMEA 客戶在季節性較淡的暑假後回流;但亞太地區將因大中華市場逢十一黃金週假期而略有下降,部分抵銷前述增幅。就北美市場而言,我們預期 Invisalign 量將較前一季增加,反映季節性較強的一季;但仍會受到哈維與艾瑪颶風部分遺留影響的抵銷。就掃描儀業務而言,我們預期將小幅季增,反映資本設備在年底通常較強的需求。第四季的季增反映第三季北美 GP 高峰會所取得訂單的效益,以及全球擴張。
As Joe commented earlier, this quarter, we produced 2/3 of SDC aligners. However, we expect our aligner shipments to SDC to be down sequentially in anticipation of a production shift back to their own internal manufacturing.
如 Joe 先前所評論,本季我們生產了 SDC 隱形牙套的 2/3。不過,考量到其生產將轉回其自有內部製造,我們預期我們對 SDC 的隱形牙套出貨量將較前一季下滑。
With this as a backdrop, we expect the fourth quarter to shape up as follows: Invisalign case volume is expected to be in the range of 245,000 to 250,000 cases, up approximately 29% to 32% over the same period a year ago. We expect Q4 net revenues to be in the range of $391 million to $398 million, an increase of approximately 33% to 36% year-over-year. We expect Q4 gross margins to be in the range of 75% to 75.5%, reflecting higher ASPs, partially offset by higher expenses as we regionalize our treatment planning operations. We expect Q4 operating expenses to be in the range of $198 million to $202 million, up on a sequential basis to reflect our continued investment in go-to-market activities. Q4 operating margin should be in a range of 24.3% to 24.8%. Our effective tax rate, including an excess tax benefit of about $1 million, should be approximately 22%. We expect a $1.5 million loss related to our share of SmileDirectClub. And diluted shares outstanding should be approximately 81.9 million, inclusive of any share repurchases. Taken together, we expect our Q4 diluted earnings per share to be in the range of $0.92 to $0.95. In addition, as we continue to operational -- as we continue our operational expansion efforts, we expect CapEx for Q4 to be approximately $55 million to $60 million, and we expect depreciation and amortization to be $10.5 million to $11 million.
在此背景下,我們預期第四季將如下發展:Invisalign 病例量預計介於 245,000 至 250,000 例,較去年同期約成長 29% 至 32%。我們預期第四季淨營收介於 3.91 億至 3.98 億美元,年增約 33% 至 36%。我們預期第四季毛利率介於 75% 至 75.5%,反映較高的平均銷售價格(ASP),但部分被我們將治療規劃作業區域化所帶來的較高費用所抵銷。我們預期第四季營業費用介於 1.98 億至 2.02 億美元,較前一季增加,以反映我們持續投資於市場推進(go-to-market)活動。第四季營業利益率應介於 24.3% 至 24.8%。我們的有效稅率(包含約 100 萬美元的超額稅務利益)應約為 22%。我們預期與我們持有 SmileDirectClub 權益份額相關的損失為 150 萬美元。而稀釋後流通在外股數應約為 8,190 萬股,包含任何股票回購的影響。綜合以上,我們預期第四季稀釋後每股盈餘(EPS)介於 0.92 至 0.95 美元。此外,隨著我們持續推動營運擴張—隨著我們持續推動營運擴張工作,我們預期第四季資本支出(CapEx)約為 5,500 萬至 6,000 萬美元,並預期折舊與攤銷為 1,050 萬至 1,100 萬美元。
With that, I'll turn it back over to Joe for final comments. Joe?
接下來,我把時間交還給 Joe 做最後的評論。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, John. We're pleased with the performance of the business and feel good about the overall momentum and strength of Align. With that, we'll open up the call for any questions. Operator?
謝謝,John。我們對業務表現感到滿意,也對 Align 整體的動能與實力感到樂觀。接下來我們開放提問。接線員?
Operator
Operator
(Operator Instructions) Our first question comes from the line of Robert Jones with Goldman Sachs.
(接線員指示) 我們的第一個問題來自高盛(Goldman Sachs)的 Robert Jones。
Robert Patrick Jones - VP
Robert Patrick Jones - VP
A very big step up in ASPs. And John, I know you touched on some of the factors there, FX, mix and price increases. But it does look like that you're calling for this to be sustainable, at least to the end of the year. So I was maybe hoping you could just talk about the drivers, and I guess maybe specifically mix and the price increases where I'd be most interested in what's driving that and why you think that looks like it'll hold at least through the end of this year?
ASP 有非常大幅度的提升。John,我知道你提到了一些因素,包括匯率、組合與漲價。但看起來你們認為這是可持續的,至少到今年年底。所以我想請你談談驅動因素;我想我特別關心的是組合與漲價,想了解是什麼在推動,以及你為何認為至少到今年年底都能維持?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. Good question. You're right. We did see some mix benefits with some volume that was -- that came through Asia. So that helps us from an overall standpoint. We saw some FX favorability that came in this quarter. As you've noted, we have price increase that is in our numbers as well, partially offset by some discounting. So net it all together, we feel that for the fourth quarter, it should be flat to slightly down from where we end in Q3.
是的。問得好。你說得對。我們確實看到一些組合上的利多,因為有部分量—是來自亞洲。因此從整體角度來看,這對我們有幫助。本季也出現了一些有利的匯率因素。如你所指出,我們的數字中也包含了漲價因素,但部分被一些折扣所抵銷。因此綜合來看,我們認為第四季應會與第三季結束時的水準持平到略為下滑。
Robert Patrick Jones - VP
Robert Patrick Jones - VP
Okay. Got it. And then I guess just on the patient financing interesting new wrinkle. Joe, was hoping maybe you could talk about the opportunity there. Any data or survey work you guys have done that might help us get our head around how many people actually maybe go to doc locator or go to see a doctor about pursuing Invisalign, but ultimately, don't elect to do the treatment because of cost? It might help us frame how this might help the opportunity there.
好的。了解。接著我想問病患融資這個有趣的新變化。Joe,希望你能談談這方面的機會。你們是否有任何數據或調查,能幫助我們理解:有多少人可能會去使用醫師搜尋(doc locator)或去看醫師以評估 Invisalign,但最後因為費用而沒有選擇治療?這可能有助於我們衡量這對機會的影響。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. Bob, it's a good question. We don't have any real statistics to tell you how many people go on doc locator and how many -- but we can tell you, you can -- from our consumer capture efforts and we talked about the concierge service. This is one of the big items that consumers have to deal with. Often, orthodontists also ask for a large down payment upfront too that even if the customer can avoid credit, it's still a pretty big hit from a cash standpoint up front. So we think this will be a good factor, significant factor for us in helping to bring more consumers into Invisalign. But we don't have any statistics right now to tell you exactly what that might be. And I'd say just stay with us and as we go through this, we'll be able to give you more and more specifics on it.
是的。Bob,這是個好問題。我們沒有任何確切統計可以告訴你有多少人會上 doc locator、以及有多少人—但我們可以告訴你,從我們的消費者導流(consumer capture)工作,以及我們提到的禮賓服務(concierge service)來看,這是消費者必須面對的一個重大項目。這是消費者經常需要處理的問題之一。而且矯正醫師往往也會要求相當高的前期頭期款;即使客戶可以避免使用信用貸款,從現金角度來看,前期仍是一筆不小的負擔。因此我們認為,這將是一個良好且重要的因素,幫助我們把更多消費者帶入 Invisalign。但目前我們沒有任何統計可以精確告訴你規模會是多少。我想你就持續關注我們,隨著我們推進,我們將能提供越來越多更具體的資訊。
Operator
Operator
Our next question is from the line of Steve Beuchaw with Morgan Stanley.
我們的下一個問題來自摩根士丹利(Morgan Stanley)的 Steve Beuchaw。
Stephen Christopher Beuchaw - Equity Analyst
Stephen Christopher Beuchaw - Equity Analyst
Two from me on the same basic concept, and it's about the trajectory of investment in the business. I have to imagine, you feel happy about on the marketing spend trajectory and on the efforts in Asia that these have paid off as well as they have. You gave a couple of interesting statistics on -- I think it was 60% growth in marketing spend and something like a tripling of the customer base. And I believe that was the broader Asia. Could you talk about: one, how you think about the growth of marketing spend and the commercial team from here? And then, two, similar question more specific to Asia, how you think about the remaining runway for customer acquisition, considering how much success you've had and how much you probably learned about how things are working there?
我有兩個問題,圍繞同一個基本概念:也就是對業務投資的軌跡。我想你們一定對行銷支出軌跡以及在亞洲的努力感到滿意,因為這些投入的回報看起來相當不錯。你們提供了幾個有趣的統計—我記得是行銷支出成長 60%,以及客戶基礎大約成長到三倍。我相信那指的是更廣泛的亞洲地區。能否談談:第一,從現在開始你們如何看待行銷支出與商務團隊的成長?第二,類似的問題但更聚焦在亞洲:考量你們已取得的成功以及你們可能已學到當地運作方式,你們如何看待客戶獲取(customer acquisition)剩餘的成長跑道?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes, Steve, it's Joe. On the marketing spend, I'd just say we just continue to do what we can in the sense of driving volume. And there's no formulated methodology we have here. Obviously, we focused on teens in a big way in North America to get the lift that we had. That spend also has been -- I think really refined in the sense of how much is social media, how much go to the mother segment, how much go to the teens and how it's done. So I feel there's a lot of accuracy and sophistication in sense of how we go about it. So but we do know that we had a pretty big signal in the sense of being able to spend more in that channel and see an increase in our orders. Although we keep spending where we can, I think a broader question in that, I believe in your second one is how we do this overseas, too. In North America, a lot of our marketing dollars on teens, we're focused in the third quarter and the second quarter also. We will look at translating what we're learning in the United States overseas, and we've had a pretty good response from our teen standpoint in China also. Now we have some restrictions in the sense of how you can advertise in certain geographies and we have to be compliant in that sense. But we will be smart in the sense of how we use the advertising dollars. From an Asia runaway standpoint, I mean, this is -- we talked about going wide in the business. You saw we trained another 1,000 docs overall in China for the quarter. There's a direct correlation in the sense of being able to train those docs and we see the increase in orders going forward. Remember, our penetration rates in places like China are still relatively thin, when you think about the available population, also India. We're really just getting started in Korea and Taiwan. Australia we saw terrific growth there too. And that's a market that we've had fairly good penetration rates in over the years and so, there's different formulas we have to use for different geographies in the sense of adding sales people, adding docs, like in Australia, it's a different deal in the sense of, it's more like North America where it's advertising in specificity where you spend from a sales standpoint that helps in that way. But I know I'm not helping you a lot, Steve, in the sense of being able to model that. But I'll tell you that we obviously watch this closely. We want to invest in the sense of where we get the biggest return and we do watch that part also.
是的,Steve,我是Joe。關於行銷支出,我想說我們會持續盡我們所能去帶動量能。而且我們這邊並沒有一套既定的方法論。很明顯地,我們在北美大幅聚焦青少年族群,以取得我們所看到的拉升效果。我認為那筆支出也已經——在社群媒體占比多少、投向母親族群多少、投向青少年多少,以及執行方式等面向——變得更精準、更精煉。所以我覺得我們在做法上有相當高的準確度與成熟度。不過我們也確實看到一個相當明顯的訊號:在那個渠道增加投放,就能看到訂單增加。雖然我們會在可行之處持續投放,但我想你第二個問題更廣泛的部分,是我們如何也在海外這麼做。在北美,我們針對青少年的行銷預算,第三季投入很多,第二季也有。我們會把在美國學到的做法移轉到海外;而且從青少年面向來看,我們在中國也得到相當不錯的回應。當然,在某些地理區域,廣告投放方式會有一些限制,我們必須在合規的前提下進行。但我們會很聰明地運用廣告預算。從亞洲快速擴張的角度來看,我是說——我們談過要把業務做廣。你也看到我們這一季在中國總共又訓練了另外1,000位醫師。訓練這些醫師與我們後續看到訂單增加之間,有直接的相關性。請記得,像中國這樣的地方,若以可觸及人口來看,我們的滲透率仍相對偏低;印度也是。我們在韓國與台灣其實才剛起步。澳洲我們也看到非常亮眼的成長。而那是一個多年來我們滲透率相對不錯的市場,所以在不同地理區域,我們必須用不同的公式:例如增聘業務人員、增加醫師數;像澳洲就不太一樣,更像北美——從業務端來看,重點在於更精準地投放廣告、把錢花在對的地方,這會在那方面帶來幫助。但我知道,Steve,就你要能建模這件事而言,我可能沒有幫到你太多。不過我可以告訴你,我們顯然會非常密切地監控這些。我們希望把投資放在能帶來最大回報的地方,這一塊我們也會持續關注。
Stephen Christopher Beuchaw - Equity Analyst
Stephen Christopher Beuchaw - Equity Analyst
That is really helpful color. If I could just sneak in one housekeeping item. I wonder if you have any updates on timelines in the U.S. for mandibular advancement and for iGo?
這些補充說明真的很有幫助。如果我可以再插入一個例行事項。想請問你們在美國關於下顎前移(mandibular advancement)以及 iGo 的時程,有沒有任何更新?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
On mandibular advancement, we expect to hear back from the FDA in December sometime. And that's all we know. It's really -- it's lights out when you do that. When you submit your data, and then basically the FDA kind of goes behind closed doors and kind of works through it. But we feel we submitted good data. And we'll just wait and see what they have to say in December. And now from an iGo standpoint, remember, we keep better rating on iGo in different parts and different geographies in the sense of the product itself and how that interacts with the doc and the patient. And we've had -- we continue to do well with that product line. But you'll see more data on that on iGo and iGo's success as we get into -- as we report the fourth quarter next year, we'll have more specificity on it.
關於下顎前移,我們預期會在12月某個時間點收到 FDA 的回覆。目前我們只知道這些。這真的——一旦你做了那件事就像熄燈一樣。你提交資料之後,基本上 FDA 會在非公開的情況下進行審查並處理。但我們覺得我們提交的是很好的資料。我們就等著看他們在12月會怎麼說。至於 iGo,請記得,我們在不同零件、不同地理區域上,持續把 iGo 做得更好——就產品本身,以及它如何與醫師和病患互動而言。而且我們在這條產品線上——我們持續表現得不錯。不過,隨著我們進入——等到明年我們公布第四季時,你會看到更多關於 iGo 的資料,以及 iGo 成功表現的更具體細節。
Operator
Operator
Our next question is from the line of John Kreger with William Blair.
下一個問題來自 William Blair 的 John Kreger。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Joe, obviously, the year's played out very, very well in terms of volumes. Can you just talk about how the infrastructure is holding up? Are you starting to see any bottlenecks or choke points that could be challenges if the demand continues to be this strong?
Joe,很明顯今年在量能方面的表現非常、非常好。你能否談談基礎設施的承載狀況如何?如果需求持續這麼強勁,你們是否開始看到任何瓶頸或卡點,可能會成為挑戰?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
John, it's a great question. Obviously, when you start to grow at this rate, above what we predicted, we've been able to stay ahead from a manufacturing standpoint, we always go to certain amount of buffer capacity so we can cover things like this. Initially, we had a little bit of trouble in the sense of ClinCheck and our people that actually do the ClinCheck pieces and -- but we experienced that back actually in January or so, we adjusted to give us extra capacity for the year. So right now, we're in good shape. It's a good thing about this business in the sense that we can adjust capacity pretty quickly within a certain number of weeks and months when we have these kinds of things. But we're trying to anticipate and lay resources in ahead of these things so we get into a situation where we can't handle demand.
John,這是個很好的問題。很明顯地,當你以這樣的速度成長、且高於我們原先預測時,從製造端來看我們一直能保持領先;我們一向會保留一定程度的緩衝產能,以便因應這類情況。一開始我們在 ClinCheck 以及實際負責 ClinCheck 作業的同仁方面——確實遇到一點狀況;但其實我們在大約1月左右就已經經歷過一次,並做了調整,讓我們在今年有額外的產能。所以目前我們狀況良好。這個業務的一個優點是,當遇到這類情況時,我們可以在幾週到幾個月的時間範圍內相當快速地調整產能。但我們也在努力提前預判並預先配置資源,避免出現我們無法承接需求的情況。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Great. And then maybe any early thoughts on 2018 and sort of key puts and takes? For example, should we think about the storm's here in North America, as maybe causing it to start more slowly or maybe giving you a little bit of pent-up demand as you move into next year?
很好。那麼,對於2018年是否有任何初步想法,以及一些關鍵的利多利空因素?例如,我們是否應該把北美的風暴視為可能導致起步較慢,或是反而在進入明年時帶來一些被壓抑的需求?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I wouldn't call the storms material at all, John. So I won't even consider that in the equation. Right now, we kind of talked about this. We anticipate that there will be 2018 questions. And look, we have good momentum now you can see us going into the fourth quarter. And I think John has given you some really strong indications of where the fourth quarter is going to be and so we try to be as specific as we could to help in that sense. But we're really not ready to get into conjecture on 2018 at this point.
John,我不會把那些風暴稱為有任何重大影響。所以我甚至不會把它納入方程式。我們現在也算談過這點。我們預期大家會問2018年的問題。而且你看,我們目前動能很好,正進入第四季。我想 John 已經給了你一些非常強的指引,說明第四季可能會走向哪裡,因此我們也盡可能具體地提供資訊來協助你。但就目前而言,我們還沒有準備好去對2018年做推測。
Operator
Operator
Our next question is from the line of Jon Block with Stifel.
下一個問題來自 Stifel 的 Jon Block。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
I'll ask 2 questions as well. Maybe just the first one, the international case volume number was tremendous, notably APAC. You mentioned the trained docs, and that was certainly big. But is some of that, Joe, also due to the local treatment planning facility that just opened up? Or is arguably is that even too soon to be yielding benefits and that still might be on the come in subsequent quarters?
我也想問兩個問題。也許先問第一個,國際病例量非常可觀,特別是亞太地區(APAC)。你提到受訓醫師,這當然是很大的因素。但 Joe,這其中是否也有一部分是因為剛啟用的在地治療規劃中心?或者說,現在就看到效益是否還太早,可能要到後續幾季才會逐步顯現?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I'd say right now -- I wouldn't call any of that extra volume right now, Jon, associated with those. In fact, we just got back from -- we were in Germany just last week to take a look at our treatment facility, we opened up in Cologne there. And honestly it's just starting to get ramped up. The initial indications is like, just like in China. These are really good, they interface well with customers. The teams there are very excited in the sense of what they can do. And you just get -- getting close to those customers and being in that geography from a cultural and a time frame standpoint is really critical. So no, that hasn't -- that really hasn't impacted volume yet. But we'd give a report as we get into the next year and as this becomes a little more mature. I mean, we obviously put that in there because we think mid-term, longer-term, this is going to be a volume driver for us.
我想就目前而言——Jon,我不會把現在的任何額外量歸因於那些因素。事實上,我們剛從——上週我們人在德國,去看了我們的治療中心,我們在科隆(Cologne)那邊剛開幕。老實說,它才剛開始爬坡。初步跡象就像在中國一樣。這些中心真的很不錯,和客戶的介面配合得很好。那邊的團隊也非常興奮,因為他們能做的事情很多。而且從文化與時區的角度來看,貼近客戶、身處當地地理位置是非常關鍵的。所以不,這還——這確實還沒有影響到量。但我們會在進入明年、且這項業務更成熟一些時再做報告。我的意思是,我們之所以提到它,是因為我們認為在中期、長期,這將會成為我們的量的驅動因素。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Got it. You actually just answered the questions with that very last statement. That's perfect. And then just to shift gears, patient financing pilot. I want to make sure I've got my arms around this correctly. So the doc gets a treatment fee, less Align's lab fee. So are you guys the one taking on the financing risk? And if so, should we think about it as a potential long-term tailwind to sort of your realized ASP offset by what could be sort of this theoretical bad debt expense from the consumer? Maybe if you can just talk through that?
了解。你其實用最後那句話就回答了問題。非常好。接著換個話題,關於病患融資試點(patient financing pilot)。我想確認我是否理解正確。所以醫師收取治療費用,扣除 Align 的技工所費用(lab fee)。那麼融資風險是由你們承擔嗎?如果是的話,我們是否應該把它視為對你們已實現 ASP 的一個長期利多,但同時會被消費者端可能產生的理論上壞帳費用所抵銷?能否請你說明一下?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
John, can you handle that?
John,你可以回答這題嗎?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, I'll take this one, Jon. No, it's a third-party that will take on any of the -- any of those financings. So the bad debt or anything else that comes with this would be a third-party. It would not be associated with us at all.
可以,Jon,這題我來回答。不,是由第三方承作並承擔任何——任何這類融資。因此壞帳或任何伴隨而來的事項都會由第三方承擔。完全不會與我們有任何關聯。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Okay. So zero impact to your ASPs. Perfect. I'll take the rest offline.
好的。所以對你們的 ASP 完全沒有影響。太好了。其餘我會私下再跟進。
Operator
Operator
Our next question is from the line of Matt O'Brien with Piper Jaffrey.
下一個問題來自 Piper Jaffrey 的 Matt O'Brien。
Unidentified Analyst
Unidentified Analyst
This is Kevin on for Matt today. I wanted to take a moment on iTero, which seems to be the focus for this year and beyond and with record shipments. I'm just curious how you're looking at the trends for case submissions and the broader strategy on the ground for iTero. It seems like a bigger piece than we previously anticipated. I know you mentioned -- and the second part of the question is I know you mentioned in the prepared remarks about the lower patient traffic in summer holidays. Just wanted to reconcile the sales effort on the scanners into GP offices? And kind of how does that relate to the lower volume in the quarter? It seems a bit of a mismatch.
我是 Kevin,今天代 Matt 提問。我想花點時間談談 iTero,看起來這是今年以及未來的重點,而且出貨量創新高。我想了解你們如何看待病例提交(case submissions)的趨勢,以及 iTero 在第一線的更廣泛策略。看起來它所占比重比我們先前預期的更大。我知道你在事先準備的發言中提到——第二部分問題是,你提到暑期假期期間病患流量較低。我想把這點和你們將掃描儀銷售推進到一般牙科(GP)診所的銷售力道做個對照。以及這和本季較低的量之間是什麼關係?看起來有點不一致。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Remember, last year, Kevin, we're shipping a lot from backlog on the volume piece. What you're seeing this year is a pure demand signal. There's nothing really coming-out of backlog. So I think if you're talking about that discrepancy, that's the one I'd point out. I think on your broader question, on the volume of the business, I think it's important for you to understand that when we talk about sales last year by iTero, it's broadly a North American business. What we're seeing now, we're seeing an increased uptake in Europe. We've had a -- we just approved in Japan, we've had some significant shipments in Japan in the third quarter, also we'll move into Asia broadly more next year or so. I'd say you see the business is just -- it's getting broader internationally and that adds to the volume also. But in the United States, I hear in your comments, I think you understand that we have a really good amount of orthodontic penetration with iTero and more and more of our sales are moving into GPs. And so that's one of the reasons we put together the Patterson Dental distribution agreement because of their strong position with GPs and help us through. So we have some work to do on sort of workflow and areas like that to be more viable in that channel. But we've got really good pick up and we're enthusiastic about the future at North American channel for GPs too.
Kevin,記得去年在量的部分,我們有很多是從積壓訂單(backlog)出貨。你今年看到的是純粹的需求訊號。基本上沒有什麼是從積壓訂單釋出的。所以如果你在談那個落差,我會指出這一點。至於你更廣泛的問題、關於業務量,我認為你需要了解的是:當我們談到去年 iTero 的銷售時,它大致上是北美的業務。我們現在看到的是歐洲的採用率提升。我們在日本剛獲核准,第三季在日本也有一些顯著出貨,另外在接下來一年左右也會更廣泛地推進亞洲。我會說你看到這項業務——它正在國際上變得更廣,這也會帶動量的增加。但在美國,我從你的評論中聽得出來,我想你也理解:iTero 在齒顎矯正(orthodontic)領域的滲透率已經相當高,而我們越來越多的銷售正在轉向一般牙科醫師(GP)。因此我們才會與 Patterson Dental 簽訂經銷協議,因為他們在 GP 端的地位很強,能協助我們推進。所以在工作流程等方面,我們還有一些工作要做,讓它在該通路更具可行性。但我們已經看到很好的成長動能,對北美 GP 通路的未來也很有信心。
Unidentified Analyst
Unidentified Analyst
Okay, great. I mean -- the second question kind of comes from China. I think a few folks touched on this, too. Just wanted to discuss just the utilization trends in that market and the strategy that's kind of done differently there that you would highlight versus the rest of the international markets. Is there anything on the ground that I'm missing driving this? Or is it just continued adoption, training and utilization as you would expect?
好的,很棒。第二個問題是關於中國。我想也有幾位提到這點。我想討論一下該市場的使用率(utilization)趨勢,以及你們在那裡採取、相較其他國際市場有何不同的策略重點。在第一線是否有我忽略、正在推動這些表現的因素?還是就如你們預期的那樣,只是持續的採用、培訓與使用率提升?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Continued adoption, training and utilization just as you described it, Kevin. I wish I could make it sound harder and more sophisticated. But it's about getting resources in place and moving them through. Now you know we just put up a treatment planning facility in China. And that's really that we're ramping up well. We're getting good customer feedback. And so we'll continue to do more resources to enhance that position in China in the future.
就是持續的採用、培訓與使用率提升,正如你所描述的,Kevin。我希望我能把它講得更困難、更精密一些。但其實就是把資源到位,並推動它們運作起來。你也知道我們剛在中國設立了一個治療規劃中心。而且目前爬坡狀況很好。我們也收到不錯的客戶回饋。因此未來我們會持續投入更多資源,以強化我們在中國的布局。
Operator
Operator
Our next question is from the line of Erin Wright with Credit Suisse.
下一個問題來自 Credit Suisse 的 Erin Wright。
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Just as a follow-up on sort of the scanners. I guess, what sort of traction are you seeing for kind of stand-alone, I guess, versus sort of a continuing closed architecture assistance just given sort of the distribution shift that, shift that we've been seeing kind of in the periphery in the U.S. and is there sort of stocking dynamics that we should be considering here in near-term?
就掃描器這塊我再追問一下。我想問的是,就獨立式(stand-alone)的採用動能,相較於持續性的封閉式架構輔助(closed architecture assistance),你們目前看到的牽引力如何?考量到我們在美國周邊市場看到的通路轉移(distribution shift),以及短期內是否有任何庫存備貨(stocking)動態是我們需要納入考量的?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Erin, I missed that question. You talked about -- can you just rephrase the first one
Erin,我剛剛沒聽清楚那個問題。你提到的是——你可以把第一個問題再換個說法嗎?
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
ITero. Sorry.
iTero。抱歉。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes, I know, I got iTero. But what's underneath that? What...
是的,我知道,我聽到 iTero 了。但你想問的核心是什麼?什麼……
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
What do you mean by closed systems?
你說的封閉系統是什麼意思?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. Closed systems? Yes.
對。封閉系統?對。
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Like closed architecture systems involving like chair size (inaudible) and...
像是那種封閉式架構系統,例如椅旁尺寸(聽不清)以及……
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
You mean like a Sirona system that's -- we don't -- we are completely open. But at Sirona, they're capable of doing a scan and sending it into us. So or you can bypass an impression with a Sirona scanner. You can't necessarily get simulation and a lot of visualizations and things that we offer on the iTero side. But -- does that answer -- and then when you talk about -- did you -- you talked about capacity on iTero or...
你是指像 Sirona 那種系統——我們不是——我們是完全開放的。不過在 Sirona 那邊,他們可以完成掃描並把資料傳給我們。所以你也可以用 Sirona 掃描器繞過傳統取模(impression)。但你不一定能在 iTero 端獲得我們提供的模擬(simulation)以及大量視覺化呈現等功能。不過——這樣有回答到嗎——另外你提到的——你是在問 iTero 的產能,還是……
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Yes, or any sort of stocking with distributor relationships there that we should be thinking about?
對,或是透過經銷商關係是否會有任何備貨(stocking)情況,是我們需要留意的?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Oh, no. I understand what you mean. Nothing like the Patterson Sirona thing. Don't worry about any kind of stocking things affecting our numbers in any material way.
喔,不會。我懂你的意思。沒有像 Patterson/Sirona 那種情況。不用擔心任何備貨因素會以任何實質方式影響我們的數字。
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Okay, great. And then can you give us an update on the SmileDirectClub and how that sort of resonating with customers? And how you weigh sort of that direct-to-consumer relationship with also practitioners as well?
好的,很好。另外,你能否更新一下 SmileDirectClub 的狀況,以及它在客戶端的反應如何?以及你們如何權衡這種直面消費者(direct-to-consumer)的關係,同時也兼顧與臨床醫師(practitioners)的合作?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. I mean, our relationship with SmileDirectClub is good. We value it. We've -- I think we're very synergistic in the sense of how we work with one another. Remember, those are SmileDirect's customers. We don't see them, we don't really experience them. We just do what SmileDirectClub asks us to do, we do it. Obviously, a part of your question is a lot of consternation in the orthodontic channel about doctor directed and kind of systems that would be more of a digital dentistry -- remote kinds of things that were -- it's not involved in the doctor's office. Again, that's not us. We're not part of that. SmileDirectClub really controls that and holds it. So I mean there is a market for this. SmileDirectClub continues to do a great job in the market and grow pretty substantially. But it would be stupid to ignore that there is a certain amount of consternation in the marketplace and push back. But I think SDC continues to do a great job out there.
可以。我的意思是,我們與 SmileDirectClub 的合作關係很好。我們很重視它。我認為我們在合作方式上具有很強的協同效應。請記得,那些是 SmileDirect 的客戶。我們不會見到他們,也不太會直接接觸或體驗到他們。SmileDirectClub 要我們做什麼,我們就做什麼。很明顯,你問題的一部分涉及到矯正通路(orthodontic channel)對於「由醫師主導」以及某些更偏向數位牙科——遠距(remote)類型、且不在醫師診所內進行的系統——所產生的許多疑慮與不滿。再次強調,那不是我們。我們不屬於那一部分。SmileDirectClub 真正掌控並承擔那一塊。所以我的意思是,這確實有市場。SmileDirectClub 持續在市場上做得很好,並且相當大幅度地成長。但如果忽視市場上確實存在一定程度的疑慮與反彈,那就太愚蠢了。不過我認為 SDC 仍然在外部市場表現得很出色。
Operator
Operator
The next question is from the line of Richard Newitter with Leerink Partners.
下一個問題來自 Leerink Partners 的 Richard Newitter。
Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst
Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst
Joe, I just wanted to start, your growth trajectory continues to accelerate. And you know, you're at a level, is some pretty enormous year-over-year numbers here. And I was just wondering if you could reflect a little bit upon -- the age old question we always ask, you're balancing, driving future growth through reinvestment and dropping through to the bottom line and as we kind of think about some of these marketing initiatives that have clearly been paying off, it sounds like you guys are probably at a point where teens inflecting and you might want to dial forward some of these initiatives. And is that the way to think about it that you could be at a tipping point here or inflection point in adoption and you guys are going to kind of put the gas pedal on expenses? Or how should we think about philosophically your view of growth versus reinvestment?
Joe,我想先從你們的成長軌跡談起,你們的加速仍在持續。而且你知道,你們目前的年增數字已經相當龐大。我想請你稍微回應一下——這個我們一直會問的老問題:你們如何在透過再投資(reinvestment)推動未來成長,與讓獲利落到最終損益(bottom line)之間取得平衡?當我們思考一些顯然已經奏效的行銷計畫時,聽起來你們可能正處在一個「青少年(teens)」需求開始轉折(inflecting)的階段,並且可能想要加大這些計畫的力度。那是否可以這樣理解:你們可能正處於採用率的臨界點或拐點,接下來會在費用端踩下油門?或者從理念上,我們應該如何理解你們對「成長」與「再投資」之間取捨的看法?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Rich, I'd start and I just turned your attention to how underpenetrated we are in this marketplace. I mean, it's incredible, right? Globally, we can do 60% to 70% of the orthodontic cases out there today, we have 8%. And so a lot of the investments and the things that we make whether its recruiting new doctors in China or if it's targeting moms and teens here in the United States, is about really driving the penetration that there's an entitlement in this business we should have based on what patients want and based on what our technology can deliver. I know there's always questions on leverage out there, our operating profit was over 25%. Obviously, it was helped by SDC this quarter and it's significant. But we showed good leverage this quarter despite exchange and despite what I'd call kind of an unusual from an SDC standpoint. So I would say we're getting some leverage in this business. But I don't expect material change in the sense of the input-output ratio of this business. We have to continue to invest aggressively in forward sales forces, in marketing, especially in technology, too, to stay ahead and to penetrate more of the marketplace. So we've always said that our goal is 25% to 30% operating profit in this business. We could do that tomorrow if we wanted to, you wouldn't like the growth numbers. We're -- right now, we're going to get as close to that lower end and we keep working that piece and we feel good about the trade-offs that we're actually administering right now between volume and margin. Does that make sense, Richard?
Rich,我會先請你注意我們在這個市場的滲透率有多低。我的意思是,這很驚人,對吧?以全球來看,今天外面的矯正病例中,我們可以處理 60% 到 70%,但我們只拿到 8%。因此,我們做的許多投資與措施——不論是在中國招募新醫師,或是在美國這裡鎖定媽媽族群與青少年——都是為了真正提升滲透率;基於病患想要的,以及我們技術能交付的成果,這個業務本來就「理應」擁有更高的滲透。我知道外界總會問到營運槓桿(leverage),我們的營業利益率(operating profit)超過 25%。顯然,本季有 SDC 的助益,而且影響顯著。但即便在匯率影響之下、以及我所稱從 SDC 角度看有些不尋常的情況之下,我們本季仍展現了不錯的槓桿。所以我會說,我們在這個業務上確實正在取得一些槓桿效益。但我不預期在這個業務的投入—產出比(input-output ratio)上會出現實質性的改變。我們必須持續積極投資於前端銷售團隊、行銷,尤其也要投資技術,以保持領先並進一步滲透市場。因此我們一直說,我們在這個業務的目標是 25% 到 30% 的營業利益率。如果我們想要,明天就能做到,但你不會喜歡那樣的成長數字。我們——目前會盡量靠近那個區間的下緣,並持續把這一塊做好;我們對於目前在量(volume)與毛利/利潤率(margin)之間所做的取捨感到滿意。Richard,這樣說有道理嗎?
Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst
Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst
Yes. It makes a lot of sense. I think a number of investors would agree that you're striking the right balance and the trade-offs there. My second question, just on teen. Can you break out a little bit, your continued deceleration that we're seeing in that category, I guess a lot of it was helped outside the U.S. but in North America, what kind of traction are you getting with the GP channel in teen. Obviously, orthodontic channels have been a little bit more dominant there. But are you starting to see some inflection on the GP side with that segment?
有。非常有道理。我想不少投資人會同意,你們在平衡與取捨上做得很到位。我的第二個問題是關於青少年(teen)。你能否再拆解一下我們在該類別看到的持續放緩(deceleration)?我想其中不少是由美國以外市場所帶動,但在北美這邊,你們在青少年市場透過全科牙醫(GP)通路取得了什麼樣的進展?很明顯,矯正專科通路在那裡一直比較主導。但在那個區隔上,你們是否開始看到 GP 端出現一些拐點(inflection)?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
With the GP segment in general, I would say no. Honestly, I would say --I'd go it's helping us understand that more. And I could tell you the GP segment in the U.S. is certainly different than this segment in Germany, than it is in Japan, than it is in China. And so each one of these countries kind of has a different solution that we have to work through whether it's workflow or what preferences are or whatever. So I would not say we're in an inflection point at all with GPs. I'd say we have a lot of growth. Teen growth with GPs, not where they're focused. There's a lot of GPs won't even touch a teen. They're worried about working teens. So that's not a -- when we talk about teens, we're really talking about ortho channel utilization in the end.
就 GP 這個細分市場整體而言,我會說不是。坦白說,我會說——我會說這反而更有助於我們更了解這一點。而且我可以告訴你,美國的 GP 細分市場,確實不同於德國的這個細分市場,也不同於日本的,也不同於中國的。因此,這些國家各自都有不同的解決方案,我們必須逐一梳理,不管是工作流程、偏好或其他因素。所以我不會說我們在 GP 方面正處於任何拐點。我會說我們仍有很大的成長空間。青少年在 GP 端的成長——但那不是他們的重點。有很多 GP 甚至不會碰青少年病例。他們擔心治療青少年。所以那不是——當我們談到青少年時,最終我們其實是在談正畸通路的使用率。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Operator, I think we've got one more question, please.
接線員,我想我們還有最後一個問題,麻煩。
Operator
Operator
That question is coming from the line of Jeff Johnson with Robert W. Baird.
該問題來自 Robert W. Baird 的 Jeff Johnson。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
I'll try to be quick here as the last question. So Joe, I guess first question, just why did we see the increase in SDC volumes in the third quarter? Was there a driver of that? Was there a reason behind that? And why does it revert in the fourth quarter? Or do we just kind of live with a little bit of volatility here going forward?
我會盡量簡短,因為這是最後一個問題。所以 Joe,我想第一個問題是,為什麼我們在第三季看到 SDC 的量增加?有什麼驅動因素嗎?背後有什麼原因嗎?那為什麼在第四季又回落?還是說,往後我們就得接受會有一些波動?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I think I'll answer your last question first. You'll live with the volatility going forward, Jeff, okay? We get -- we don't control SmileDirectClub's decision-making process. I'm not quite sure exactly why we received that much more of SDC's volume. But I don't count on that going forward, and that's basically Jon's comments were in his opening about it. I wish I could be more specific about it, Jeff, but I can't and that's just a...
我想我先回答你最後一個問題。Jeff,往後你會得接受這種波動,好嗎?我們——我們無法控制 SmileDirectClub 的決策流程。我也不太確定為什麼我們會收到那麼多 SDC 的量。但我不會指望這種情況會持續下去,Jon 在開場時的評論基本上也是這個意思。Jeff,我希望我能更具體一點,但我做不到,這就是……
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Should we at all read that as a demand spike in the third quarter like all of a sudden volume came in stronger than they expected in the third quarter? Or do you think it was just them putting off some volume on you?
我們是否應該把這解讀為第三季需求突然飆升,也就是說他們第三季的量突然比預期更強?還是你認為只是他們把一些量延後到你們這邊?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Look, they continue to grow but I'd say it's a combination of both, but it's not driven discreetly by volume, I'd say.
你看,他們確實持續在成長,但我會說兩者都有一些因素,不過我不會說這是由量的變化單一、明確地驅動的。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Yes. Okay. And my last question is just on the fusion, the iTero fusion program. You lock some GPs in at some higher implied volumes there with that program. Just what's been the response to that program? Has that program taken off? Or is it taking off? And how should we think about the implications for the GP numbers from that program going forward?
是。好。那我最後一個問題是關於 fusion,也就是 iTero fusion 計畫。透過那個計畫,你們以較高的隱含量把一些 GP 鎖定住。那市場對這個計畫的反應如何?這個計畫有起飛嗎?或正在起飛?以及往後我們該如何看待這個計畫對 GP 數字的影響?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I think you got to move outside of North America in general. The biggest uptake in excitement for fusion has been outside of North America. And it's been really received extremely well. In North America, right now, we're really just getting cranked up on the fusion pieces. We'll have more for you in the fourth quarter results, Jeff.
我認為你得把視角放到北美以外的地區。對 fusion 最興奮、採用度最高的地方是在北美以外。而且市場反應非常好。在北美,目前我們其實才剛開始把 fusion 的各個部分推動起來。Jeff,我們會在第四季的結果中提供更多資訊。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Well, thank you, everyone. This concludes our conference call today. We look forward to seeing you at upcoming financial conferences and industry meetings. If you have any other questions, please contact Investor Relations. Have a great day.
好的,謝謝各位。今天的電話會議到此結束。我們期待在接下來的財務研討會與產業會議上與各位見面。如有其他問題,請聯絡投資人關係部門。祝各位有美好的一天。
Operator
Operator
Thank you. This concludes today's conference. You may now disconnect your lines at this time. Thank you for your participation.
謝謝。今天的電話會議到此結束。您現在可以掛斷電話線。感謝您的參與。